A.N. MARCHENKOVA¹, M.A. KUNST^1,2, R.R. MIFTAKHOVA³, N.Yu. USOLOVA⁴, Yu.M. ANDRIUKHINA², A.A. GAIBARYAN²

¹Republican Clinical Hospital of the MH of RT, Kazan

²Kazan State Medical University, Kazan

³Russian Research Institute of Hematology and Transfusiology of Federal Agency for Medicine and Biology, Saint Petersburg

⁴Saint Petersburg Pediatric Medical University, Saint Petersburg

  Contact:

Marchenkova A.N. ― hematologist of the Oncohematology Department

Address: 138 Orenburgskiy Trakt, Kazan, Russian Federation, 420064, tel. +7-987-270-47-93, e-mail: annz1118@inbox.ru 

Atypical chronic myeloid leukemia (aCML) is a clonal myeloproliferative disorder characterized by neutrophilic leukocytosis with dysgranulopoiesis and circulating immature granulocytes. Importantly, unlike chronic myeloid leukemia (CML), aCML has not Philadelphia chromosome or the fusion gene BCR-ABL1, as well as genes PDGFRA or PDGFRB. The case of aCML is presented because of rare occurrence of this disease, nonspecific clinical manifestations, and diagnostic difficulties of this disease. The patient G., 44 years old, was admitted to the Republic Clinical Hospital with the complains of weakness, fatigue, dizziness, periodic shortness of breath, pain in the hip joints, that did not fit the usual diagnoses. Only after careful diagnostic search, aCML was diagnosed.

Key words: chronic myeloid leukemia, atypical chronic myeloid leukemia, hyperexpression of the WT1 gene, allogeneic trasnplantation of hematopoietic stem cells, chemotherapy, tyrosine kinase inhibitors.

(For citation: Marchenkova A.N., Kunst M.A., Miftakhova R.R., Usolova N.Yu., Andriukhina Yu.M., Gaibaryan A.A. Atypical chronic myeloid leukemia (clinical case). Practical medicine. 2019. Vol. 17, № 6 (part 1), P. 84-87)

REFERENCES

1. Gematologiya: natsional’noe rukovodstvo, pod red.O.A. Rukavitsyna [Hematology: national leadership, under the editorship of O.A. Rukavitsyn]. Moscow: GEOTAR-Media, 2017. 784 p.
2. Abdulkadyrov K.M., Shuvaev V.A., Martynkevich I.S. Mieloproliferativnye novoobrazovaniya [Myeloproliferative neoplasms].
3. How I treat atypical chronic myeloid leukemia. Jason Gotlib Blood, 2017, 129, pp. 838-845. doi: https://doi.org/10.1182/blood-2016-08-693630
4. Inoue K., Ogawa H., Yamagami T., et al. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Willms tumor gene) expression levels. Blood, 1996, 88 (6), pp. 2267-78.
5. Kletzel N., Olzewski M., Huang W., et al. Utility of WT1 as a reliable tool for the detection of minimal disease in children with leukemia. Pediatr. Dev. Pathol, 2002, 5 (3), pp. 269-75. doi:10. 1007/s10024-001-0208-x.
6. Cilloni D., Gottardi E., De Micheli D., et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a usefultool for monitoring residualdisease in acute leukemia patients. Leukemia, 2002, 16 (10), pp. 2115-21. doi: 10.1038/sj.leu.2402675.
7. Cilloni D., Giuseppe S., Gottardi E., et al. WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Hematol, 2004, 112 (1-2), pp. 79-84. doi: 10.1159/000077562.
8. Cilloni D., Renneville A., Hermitte F., et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European LeukemiaNet study. J. Clin. Oncol, 2009, 27 (31), pp. 5195-201. doi: 10.1200/jco.2009.22.4865.
9. Weisser M., Kern W., Rauhut S., et al. Prognostic impact of RTPCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia, 2005, 19 (8), pp. 1416-23. doi: 10.1038/sj.leu. 2403809.
10. Candoni A., Toffoletti E., Gallina R., et al. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogenic stem cell transplantation in acute myeloid leukemia. Clin. Transplant, 2011, 25 (2), pp. 308-16. doi: 10.1111/j. 1399-0012.2010.01251.kh.
11. Gray J.X., McMillen L., Mollee P., et al. WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-transplantation. Leuk Res, 2012, 36 (4), pp. 453-8. doi:10.1016/j.leukres.2011.09.005.
12. Kwon M., Martinez-Laperche C., infante M., et al. Evaluation of minimal residual disease by real-time quantitative PCR of Willms Tumor 1 expression in patients with acute myelogenous leukemia after allogenic stem cell transplantation: Correlation with flow cytometry and chimerism. Biol Blood Marrow Transplant, 2012, 18 (8), pp. 1235-42. doi: 10.1016/j.bbmt.2012.01.012.
13. Polak J., Hajkova H., Haskovec C., et al. Quantitative monitoring of WT1 expression in peripheral blood before and after allogenic stem cell transplantation for acute myeloid leukemia-a useful tool for early detection of minimal residual disease. Neoplasma, 2013, 60 (1), pp. 74-82. doi: 10.4149/neo_2013_011.
14. Nomdedeu J.f., Hoyos M., Carricondo M., et al. Bone Marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML. Leukemia, 2013, 27 (11), pp. 2157-64. doi: 10.1038/leu.2013.111.
15. Alonso-Domingues J.M., Tenorio M., Velasco D., et al. Correlation of WT1 expression with the burden of total and residual leukemic blasts in bone marrow samples of acute myeloid leukemia patients. Cancer Genet, 2012, 205 (4), pp. 190-1. doi:10.1016/j.cancergen.2012.02.008.
16. Tamaki H., Ogawa H., Inoue K., et al. Increased expression of the Wilms Tumor gene (WT1) at relapse in acute leukemia. Blood, 1996, 88 (11), pp. 4396-8.
17. Frairia, Aydin S., Riera L., et al. WT1 expression in acute myeloid leukemia: a useful marker for improving therapy response evaluation. Blood, 2013, 122 (21), pp. 2588 (abstract).
18. Aksenova E.V. Standartizirvoannoe issledovanie ekspressii genov BCR-ABL, PRAME i WT1 u bol’nykh khronicheskim mieloleykozom: dis. … kand. med. nauk [A standardized study of the expression of BCR-ABL, PRAME, and WT1 genes in patients with chronic myelogenous leukemia. Synopsis of dis. PhD med. sciences]. Moscow, 2011. 138 p.